Generation bio reports business highlights and first quarter 2022 financial results

Company continues to optimize cell-targeted lipid nanoparticle (ctlnp) delivery system for nonviral genetic medicine applications in liver, retina and vaccines

GBIO Ratings Summary

GBIO Quant Ranking